News
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
Here's My Top Stock to Buy in August
Last year, Bank of America/Merrill Lynch released their analysis of an interesting study that examined the performance of growth stocks versus value stocks over the 90-year period from 1926 to 2016
3 Beaten-Up Biotech Stocks: Are They Bargains?
The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. (NASDAQ: CLDX), Agenus Inc. (NASDAQ: AGEN), or
The Best Marijuana and Precision Medicine Stocks to Buy Might Not Be the Companies You Think
The marijuana market may be on its way to being worth $25 billion in 2021, and advances in DNA research could lead to next-generation precision medicine worth billions of dollars in annual sales. Yet
The Best Marijuana and Precision Medicine Stocks to Buy Might Not Be the Companies You Think
The marijuana market may be on its way to being worth $25 billion in 2021, and advances in DNA research could lead to next-generation precision medicine worth billions of dollars in annual sales. Yet
The Best Marijuana and Precision Medicine Stocks to Buy Might Not Be the Companies You Think
The marijuana market may be on its way to being worth $25 billion in 2021, and advances in DNA research could lead to next-generation precision medicine worth billions of dollars in annual sales. Yet
This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug
If you look around, chances are you won't find many marijuana stocks struggling. In fact, over the trailing one-year period, 12 out of 13 pot stocks with a market cap above $200 million had risen
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
This Technology Could Make You Rich -- and Change the World As We Know It
Revolutionary, game-changing, groundbreaking.These words are probably used too often in describing new innovations. The reality is that most new products and technologies don't live up to the hype
3 Marijuana Stocks That Could Make You the Most Money in the 2nd Half of 2017
For investors who enjoyed the huge run of marijuana stocks last year, the first half of 2017 probably hasn't been as exciting. Several of the largest marijuana stocks haven't performed all that great
How Intuitive Surgical, Inc. Makes Most of Its Money
Robots aren't as common in hospitals as waiting rooms are, but there are certainly a lot of robots out there now. You can thank Intuitive Surgical (NASDAQ: ISRG) in large part. Over 4,100 of the
Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth
The single biggest problem facing engineered biology conglomerate Intrexon (NYSE: XON) heading into the second quarter of 2017 was its dependency on small- and micro-cap companies for a significant
2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively
When it comes to top-performing industries, you'd have a tough time surpassing the returns of marijuana stocks. Of the 13 marijuana stocks with a market cap in excess of $200 million, over half have
Better Buy: Exact Sciences Corporation vs. Opko Health
"It was the best of times, it was the worst of times..."Charles Dickens wasn't referring to Exact Sciences (NASDAQ: EXAS) and Opko Health (NASDAQ: OPK) when he wrote those words, but they're certainly
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
It's been a crazy year for Organovo Holdings (NASDAQ: ONVO) so far. The 3D bioprinting company's former CEO abruptly left in April. Organovo disappointed investors with its fourth-quarter and
The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
Shares of Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company focused on the development rare-disease drugs, exploded higher by 29% during the month of July, according to data from S&P
Here's Why Surgery Partners Inc. Is Sinking Today
Shares of Surgery Partners Inc. (NASDAQ: SGRY), a provider of surgical care services, tanked 52% shortly after the opening bell this morning in response to an earnings miss on the top and bottom
The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on the development of small-molecule drugs for the treatment of a variety of diseases, catapulted 41% during July
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous